| P/E (FY) | — | Sales (TTM) | $204.7M |
| Earnings (TTM) | -$104.6M | ROE | −48.64% |
| Net Margin | −70.41% | ROIC | −34.07% |
| Debt / Equity | 1.37 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −40.53% |
Maravai LifeSciences provides products that support the development of drug therapies, vaccines, cell and gene therapies, and diagnostics across North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America. It operates through the TRILINK and CYGNUS segments. The TRILINK segment manufactures products for gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents for synthesizing and modifying DNA and RNA, messenger RNA, oligonucleotides, CleanCap capping technology, and custom enzyme development.
| Market Cap | $990.3M | Trading Days | 1359 |
| 52W High | 7.44 |
| 52W Low | 1.99 |
| % Off High | −7.80% |
| YTD | 111.08% | 1Y | 158.87% |
| 3Y | −40.09% | 5Y | −83.96% |
| Since incept. (ann.) | −25.45% |
Tri Link 64% · Cygnus 36%
| Ann. Volatility (1Y) | 71.50% | Ann. Volatility (3Y) | 82.69% |
| Sharpe (1Y) | 1.70 | Sharpe (3Y) | 0.19 |
| Max Drawdown (1Y) | −29.60% | Max Drawdown (3Y) | −85.74% |
| Beta (3Y, vs SPY) | 1.96 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LBRX | LB PHARMACEUTICALS INC | $1.00B | — |
| BIOA | BioAge Labs, Inc. | $974.4M | — |
| JBIO | Jade Biosciences, Inc. | $972.4M | — |
| OLMA | Olema Pharmaceuticals, Inc. | $1.01B | — |
| ANRO | Alto Neuroscience, Inc. | $962.3M | — |
| AVTX | Avalo Therapeutics, Inc. | $1.03B | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $1.04B | — |
| GERN | GERON CORP | $930.2M | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $930.0M | — |
| PCRX | Pacira BioSciences, Inc. | $1.05B | 167.6 |
| CBIO | CRESCENT BIOPHARMA, INC. | $1.06B |
| — |
| FBRX | Forte Biosciences, Inc. | $1.06B | — |
